Huda Zoghbi was born in Beirut, Lebanon in 20 June 1954, and raised in Beirut. She loved reading works by William Shakespeare, Jane Austen and William Wordsworth in high school and intended to pursue literature at university.[11] Her mother convinced her to study biology instead, on the grounds that 'a woman growing up in the Middle East should pick a career ensuring independence and security, while she can always write on the side'.[12][11] Zoghbi was admitted as a biological sciences major at the American University of Beirut (AUB) in 1973 and entered the university's medical school 2 years later.[11]
The Lebanese Civil War began in 1976 during her first year of medical school. Although she and her classmates decided to stay at the university, after her brother was injured by shrapnel, their parents sent them to live with their sister in Austin, Texas, with plans to return the following summer.[11][13] The war, however, raged on, and Zoghbi was under the impression that school terms at American medical schools began in October, as was the case with Lebanese schools. However, in October, it was confirmed that she was still unable to return to Lebanon due to the war, and US medical schools had begun their fall term 2 months earlier. Her family friends in America suggested she apply to Vanderbilt University. Vanderbilt did not accept transfer students, but recommended Meharry Medical College instead; Meharry accepted her on the spot.[13] Despite her continued desire to return to Lebanon the next summer, on the advice of professors at AUB, she stayed at Meharry and earned an MD degree in 1979, after which she joined the Texas Children's Hospital at the Baylor College of Medicine as a pediatric resident.[11]
Zoghbi initially intended to specialise in pediatric cardiology. During her rotation at pediatric neurology, Marvin Fishman, the head of the division, convinced her that the brain was more interesting than the heart. She then started a 3-year term as a postdoctoral researcher in pediatric neurology after she finished her residency in 1982.
From 1982 to 1985, Zoghbi was a postdoctoral researcher in pediatric neurology at the Baylor College of Medicine. She became an assistant professor at the Department of Pediatrics at Baylor in 1988, and was successively promoted to associate professor in 1991 and professor in 1994.[14] At present, Zoghbi is a professor at the Department of Molecular and Human Genetics at Baylor, with appointments as a professor at the Department of Neuroscience and the Department of Pediatrics Section of Neurology and Developmental Neuroscience, the Ralph Feigin, M.D. Endowed Chair, the director of the Texas Children's Hospital Jan and Dan Duncan Neurological Research Institute, a member of the Dan L. Duncan Comprehensive Cancer Center at Baylor, and an investigator at the Howard Hughes Medical Institute.[5] She is also a member of the board of directors of Regeneron Pharmaceuticals.[1] She also served on the Life Sciences jury for the Infosys Prize in 2014.
In 1983, Zoghbi learnt of Rett syndrome from Bengt Hagberg's account in Annals of Neurology. The paper allowed Zoghbi to diagnose a five-year-old she treated at Texas Children's Hospital, and a week later she saw another patient with the same set of symptoms. When she investigated medical records, she found more cases of Rett syndrome that had been misdiagnosed. This sparked her interest in Rett syndrome, at a time when there was no report of the disease in the US.[3] An article she published in 1985[15] attracted many Rett syndrome patients to Texas Children's Hospital, giving her access to a large number of cases.[16]
Since most patients of Rett syndrome were girls, and symptoms were very consistent across patients, Zoghbi believed genetics were involved in the disease process.[3] This led her to join Arthur Beaudet's group in 1985, after finishing her term as a postdoctoral researcher, for training in genetics and molecular biology.[13] Beaudet advised against Rett syndrome as her research project since its mode of inheritance was still not obvious, and recommended a more approachable problem – spinocerebellar ataxia type 1, a dominantly inherited neurological disorder. In 1988, Zoghbi left Beaudet's group and founded her own lab at Baylor.[11] In addition to her research on spinocerebellar ataxia type 1 and Rett syndrome, Zoghbi is participating in a joint research collaboration into CDKL5 Deficiency Disorder, funded by the Loulou Foundation, Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute (NRI) at Texas Children's Hospital[17]
Following the establishment of her own lab, Zoghbi continued studying spinocerebellar ataxia type 1 (SCA1), in collaboration with Harry Orr from the University of Minnesota.[18] On the same day, 8 April 1993, both Zoghbi and Orr identified ATXN1 as the gene responsible for SCA1.[13] They determined that the disease was caused by an expansion of the glutamine-encoding CAG trinucleotide repeat in this gene, and that the younger the age of onset, the longer the CAG repeat.[19] Further work by Zoghbi, Orr and their teams demonstrated that the misfolding, aggregation, and proteasomaldegradation of the protein product of this gene, Ataxin 1, played a role in the disorder.[20]
After solving the etiology of spinocerebellar ataxia type 1, Zoghbi began studying animal genes related to balance. As Baylor's Hugo J. Bellen described the role of the atonal gene in balance in fruit flies, Zoghbi chose to study its mammalianhomolog. A member of her lab successfully cloned the mouse homolog, Math1, in 1996.[21] Her team went on to find that, in addition to its involvement in balance and coordination, Math1 is also crucial to hearing,[22] the formation of secretory cells in the gut.,[23] and neonatal respiratory rhythm and chemosensitivity in the adult brain by regulating the development of a group of hindbrain neurons.[24] Her lab has also shown that aberrant activation of Math1 could lead to medulloblastoma, a common childhood brain tumor, and that mice which did not express Math1, did not develop the tumor.[25]
Ever since Zoghbi was introduced to Rett syndrome early in her career, she has been working on the disorder alongside other research, despite the lack of enthusiasm from her colleagues, fellow researchers and funding agencies. The main reason is that very few individuals and even fewer families are available for investigation. In the 1990s, she collaborated with Uta Francke from Stanford University to identify the gene responsible for Rett syndrome. In 1992, she narrowed down the target to a section of the X chromosome.[26] In 1999, a postdoctoral researcher in Zoghbi's lab identified MECP2 as the causative gene.[27] The MECP2 protein binds methylatedcytosine (5-methylcytosine) in CpG sites, and is indispensable for almost all brain cells.[13] In the paper, she and her team demonstrated that Rett syndrome was an X-linked dominant disorder, meaning that when 1 of the 2 copies of the MECP2 gene is abnormal, Rett syndrome will result.[12]
Zoghbi's team keeps studying MECP2, and discovered in 2004 that overexpressing the protein in mouse led to an autism-like neurological disorder.[28] In 2009, she found mice deficient of the Mecp2 gene (the mouse homolog of human MECP2) had lower levels of norepinephrine, dopamine and serotonin,[29] consistent with her clinical observations of patients of Rett syndrome in 1985. Recently, Zoghbi confirmed that the MECP2 protein also bound 5-methylcytosine not in CpG sites,[30] and that restoring the level of MECP2 protein in a subset of neurons was sufficient to rescue some symptoms of Rett syndrome.[31]
After linking the gene Ataxin-1 to SCA1, Zoghbi's lab was approached by Dr. Jaehong Suh of the Massachusetts General Hospital's MassGeneral Institute for Neurodegenerative Disease to investigate the connection between ataxin-1 gene and Alzheimer's disease.[32] The subsequent study found that loss of ataxin-1 elevates BACE1 expression and Aβ pathology in mouse models, rendering it a potential contributor to risk and pathogenesis of Alzheimer's disease.[33]
^Orr, Harry T.; Chung, Ming-yi; Banfi, Sandro; Kwiatkowski Jr., Thomas J.; Servadio, Antonio; Beaudet, Arthur L.; McCall, Alanna E.; Duvick, Lisa A.; Ranum, Laura P. W.; Zoghbi, Huda Y. (1 July 1993). "Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1". Nature Genetics. 4 (3): 221–226. doi:10.1038/ng0793-221. PMID8358429. S2CID8877695.
^Cummings, Christopher J.; Mancini, Michael A.; Antalffy, Barbara; DeFranco, Donald B.; Orr, Harry T.; Zoghbi, Huda Y. (1 June 1998). "Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1". Nature Genetics. 19 (2): 148–154. doi:10.1038/502. PMID9620770. S2CID30029147.
^Amir, Ruthie E.; Van den Veyver, Ignatia B.; Wan, Mimi; Tran, Charles Q.; Francke, Uta; Zoghbi, Huda Y. (1 October 1999). "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2". Nature Genetics. 23 (2): 185–188. doi:10.1038/13810. PMID10508514. S2CID3350350.
^Collins, Ann L.; Levenson, Jonathan M.; Vilaythong, Alexander P.; Richman, Ronald; Armstrong, Dawna L.; Noebels, Jeffrey L.; Sweatt, J. David; Zoghbi, Huda Y. (6 September 2004). "Mild overexpression of MeCP2 causes a progressive neurological disorder in mice". Human Molecular Genetics. 13 (21): 2679–2689. doi:10.1093/hmg/ddh282. PMID15351775.
^ ab"Huda Yahya Zoghbi". Virtually Integrated Institutions for Clinical and Translational Research. Archived from the original on 21 October 2020. Retrieved 14 December 2018.